Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Drug ChannelsJoin Dr.Read full story pharminent May 12, 2026 (Last updated: May 12, 2026) Drug Channels Join Dr. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosisNext: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Related Stories Policy / Pricing Decoding Medicare Advantage Coding Intensity pharminent July 1, 2026 Policy / Pricing UK partners with Eli Lilly on obesity plan pharminent June 29, 2026 Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy pharminent June 24, 2026
